Covington has advised Gilead Sciences, Inc. CMS and Goodwin Procter have advised Tubulis GmbH. Gilead Sciences, Inc. has entered into a definitive agreement to acquire Tubulis...
Gilead to Acquire Tubulis in $5 Billion Oncology-Focused Transaction
Convatec Group’s £45 Million Acquisition of 30 Technology’s Antimicrobial Nitric Oxide Platform
Goodwin advised 30 Technology on the deal. 30 Technology announced the completed the sale of its antimicrobial nitric oxide platform in certain applications to Convatec Group Plc...
AbbVie’s Acquisition of DJS Antibodies
Goodwin Procter advised DJS Antibodies on the deal. AbbVie (NYSE: ABBV) announced the acquisition of DJS Antibodies Ltd (“DJS”), a privately-held UK-based biotechnology company dedicated to discovering...
Arcutis Biotherapeutics’ $400 Million Acquisition of Ducentis BioTherapeutics
Goodwin Procter advised Ducentis BioTherapeutics on the deal. Ducentis BioTherapeutics announced its acquisition by Arcutis Biotherapeutics for up to $400 million. Ducentis BioTherapeutics, a portfolio company of...
Gilead Sciences’ $405 Million Acquisition of MiroBio
Davis Polk & Wardwell, Mayer Brown, and Mishcon de Reya advised Gilead, while Goodwin Procter and Wilson Sonsini Goodrich & Rosati advised MiroBio on the deal....
Pfizer’s $525 Million Acquisition of ReViral
Goodwin advised ReViral on the deal. Clifford Chance advised Pfizer. ReViral announced its acquisition by Pfizer. Pfizer will acquire ReViral for a total consideration of up to...
EyeBio’s $65 Million Series A Financing
Goodwin advised SV Health, Jeito and Samsara BioCapital on the deal. SV Health, Jeito and Samsara BioCapital led a $65 million Series A Financing of EyeBio. EyeBio...
Viatris’ $3.335 Billion Combination of Biosimilars Portfolio with Biocon Biologics
Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a...
Centessa Pharmaceuticals’ $330 Million IPO
Wilson Sonsini Goodrich & Rosati and Goodwin Procter LLP advised Centessa Pharmaceuticals on the deal. Centessa Pharmaceuticals, a clinical-stage company employing its innovative asset-centric business model...